Antibiotic Resistance Market

Global Market Study on Antibiotic Resistance: Approval & Launch of Novel Therapeutics Aiding Market Expansion

Antibiotic Resistance Market Segmented By Pathogen such as Staphylococcus aureus, Streptococcus pneumonia, Neisseria gonorrhoeae, Enterococcus faecium, Escherichia coli, Klebsiella pneumonia, Shigella, Clostridium difficile with Mechanism of Action such as Cell Wall, Protein, DNA, RNA Synthesis Inhibitors

  • February-2021
  • PMRREP27895
  • 272 Pages
  • Healthcare

About the Report

Antibiotic resistance (ABR) happens because of excess and uncontrolled use of antibiotics. Most antibiotics are sold as over-the-counter drugs, with many people using them without getting prescriptions from a physician. Also, most physicians, especially in developing countries, prescribe antibiotics for viral diseases without diagnosing the disease properly. All these factors eventually lead to the development of antibiotic resistance.

Antibiotics are easily available through pharmacies, and growing preference for online pharmacies is also increasing the accessibility of antibiotic resistance products from key players. Manufacturers such as Pfizer Inc, Dr. Reddy’s Laboratories, and Novartis, to name a few, have well-established distribution channels and manufacturing sites in both, developing and developed regions.

In its new study, Persistence Market Research offers insights about key factors driving demand for antibiotic resistance products. The study points toward Community Acquired Bacterial Pneumonia (CABP) and Complicated Urinary Tract Infection (cUTI) being the most common conditions needing treatment. Hospital pharmacies grab more than half of the market share, globally. The report also tracks global sales of antibiotic resistance drugs in over 20 high-growth markets, along with analysis of the impact of COVID-19 on the pharmaceutical industry in general, and the antibiotic resistance space in particular.

The COVID-19 pandemic has had a mixed effect on the antibiotic resistance market. Majority of supply of raw materials required for pharma preparations comes from China, and during the lockdown, because a disrupted supply chain, manufacturing at regional and local levels got impacted.

Despite this delay, stocked up antibiotics were utilized for treatment where COVID patients were seen to develop co-infections (bacterial with coronavirus). Demand for antibiotics was low during peak lockdown periods, but soon came back to normal once these lockdowns were eased and lifted.

Find Out More about the Report Coverage


  • Pfizer Inc
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Johnsons & Johnson
  • Baxter Healthcare Corporation
  • Zydus Cadila
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Dr. Reddy’s Laboratories Ltd.
  • Mayne Pharma Group Limited.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Shanghai Pharmaceutical Group Co., Ltd.
  • Yuhan Corporation
  • Abbott Laboratories

Future of Antibiotic Resistance Market

The antibiotic resistance drug pipeline possesses a strong hope for future therapy options. Many small entrants and established players have invested in clinical trials. Commonly occurring community-acquired pneumonia (CAP) is an important cause of mortality in Asia Pacific. Large population, growing aging population, dense urbanization, and poor access to healthcare make the Asia Pacific region vulnerable to antibiotic resistance diseases.

Common etiologic pathogens such as Streptococcus pneumoniae, Mycoplasma pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Chlamydophila pneumoniae, and respiratory viruses are the most prevalent pathogens, globally. But higher incidence rate of Klebsiella pneumoniae and the presence of Burkholderia pseudomallei are unique to Asia Pacific.

Antibiotic resistance poses a threat to people worldwide, and this has created large need for new approaches to solve the problem. Life sciences and healthcare industries need to collaboratively address this threat sooner than later.

Over the past 5 years, the global antibiotic resistance market expanded at a value CAGR of 3.1%, and over the next ten years, growth will be faster at a CAGR of over 4% through 2031.

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

How will better access to antibiotics aid market expansion?

Due to slowed development of new antibiotics, very few antibiotics are left to effectively treat infections caused by multidrug-resistant bacteria and still fewer, which are affordable in developing regions. Many developing countries may not be able to save adequate resources to fight ABR.

Access to diagnostics to determine disease management and self-medication are serious issues for Asia. One such plan - the Global Action Plan on ABR, is to improve access to affordable antibiotics and facilitate implementation of this component efficiently.

The global battle against ABR needs to consider engagement of Asian countries as the use of antibiotics is very high in this region.

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

What is the impact of industry collaboration on the antibiotic resistance market?

Consolidation in the market is attributed to activities such as strategic acquisitions and collaborations. This trend is observed mainly by prominent players in this space.

  • For instance, it was in 2016 when Baxter announced the U.S. launch of the premix drug Vancomycin Injection in sodium chloride. Baxter is the only manufacturer to offer VANCOMYCIN in a premixed dosage form.
  • On December 19, 2018, Pfizer and GlaxoSmithKline announced a joint venture to create a premier global consumer healthcare company. This would help in creating a better platform for both companies.
  • In another instance, in 2016, Bavarian Nordic entered into a collaboration with Evaxion Biotech, a Danish biotechnology company, and Technical University of Denmark (DTU), for the development of a vaccine against Methicillin-resistant Staphylococcus aureus, using Evaxion's computer-based technology to discover novel antigens.

Explore Persistence Market Research’s expertise in promulgation of the business !

Why are approval and launch of novel therapeutics key to market growth?

Prominent pharmaceutical players are focusing on discovery and launch of next-generation antibiotics to treat ABR. This augmented accessibility of antibiotics in the market is expected to propel antibiotic resistance market growth. Adding to this, launches of generic products are growing stronger year on year, and are expected to increase antibiotic availability.

Melinta Therapeutics Inc., in 2019, received US-FDA approval of Baxdela™, which is fluoroquinolones antibiotic that exhibits activity against a broad spectrum of bacteria. Increasing investments in antibiotic resistance and development of novel pipelines are expected to favor growth of the antibiotic resistance industry over the forecast period.

  • In October 2018, Nuzyra was approved by FDA. This drug is a tetracycline antibiotic used for treating adults with acute skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

How do government initiatives impact demand for antibiotic resistance products?

International associations of infectious diseases and the World Health Organization (WHO) are vigorously addressing the antibiotic resistance problem, and have increased awareness, diagnosis, and treatment of infections, especially multi-drug resistance infections.

CDC (Centers for Disease Control and Prevention) and the U.S. Department of Health and Human Services are collaborating with healthcare facilities to meet goals of the 2013 National Action Plan to Prevent Healthcare-Associated Infections.

The Australian government has strategically planned to combat ABR, which includes governing antimicrobial resistance initiatives and preventive measures to control ABR spread. Greater engagement in terms of investment to fight against resistance and incorporating proper usage and stewardship practices for the use of antibiotics will aid market expansion over the coming years.


Country-wise Insights

Why is South East Asia, particularly India, witnessing significant demand for antibiotics?

Human antibiotic consumption in India is the highest in the world. It is reported that antibiotic consumption in India has increased from 3.2 billion DDDs to 6.5 billion DDDs from 2000 to 2015.

The main driving force behind the occurrence of ABR is selection pressure created due to consumption of antibiotics. Inappropriate use of antibiotics is extensive in South East Asia, and is a major contributor to the antimicrobial resistance market. Many countries in the South East Asian region now have some policies in place to deal with ABR, but most of them lack thorough implementation.

How will increasing incidence of ABR surge antibiotic resistance demand in the U.S.?

ABR infection incidence is expected to rise globally, and the U.S. can be considered a main center for ABR. Emergence of antibiotic resistance infections and increasing number of healthcare-acquired infections are increasing the patient pool in the United States.

As per CDC, an estimated >125,900 hospitalizations annually were for S. aureus infections from 1999 to 2000, including bloodstream infections and pneumonia of the isolates associated with these hospitalizations. An extensive surveillance program of nosocomial bloodstream infections in the United States showed that there was an increase in ABR rates by 3.1% every year.

What is the impact of growing contract manufacturing organizations on the Chinese antibiotic resistance market?

Recently, small and large pharmaceutical companies have become increasingly dependent on contract manufacturing and other raw material supplies. Majority of the raw materials for API manufacturing are procured from China. Large pharma companies based out of North America and Europe prefer to outsource their manufacturing capabilities. China is a preferred location in terms of cheaper resources and manufacturing workforce. For these reasons, China generates huge revenue from antibiotic resistance drug manufacturing.

How will the impressive presence of local pharma manufactures in India affect the antibiotic resistance market in the country?

Among the Asian countries, India is expected to be the leader in the antibiotic resistance market, due to the presence of many pharmaceutical companies in the country. India is a fast-growing market for antibiotic resistance drugs, and is anticipated to witness significant growth across the forecast period.

Presence of some prominent players such as Cipla, Dr. Reddy’s Laboratories, Mylan N.V, and Zydus Cadila will create remarkable returns for the region. Presence of local players not only generates revenue for the country, but also increases the accessibility of drugs for the local people.

Category Insights

How is extensive development of antibiotic resistance impacting the Industry?

Manufacturers are focusing on the introduction of antibiotic resistance drugs in the market as growing demand for these products has been forced by increasing prevalence of ABR. Gepotidacin is a drug in clinical phase 3 targeted for  uncomplicated urinary tract infection (uUTI) / gonorrhea (GC). This drug is developed by pharma giant GlaxoSmithKline plc.

Entasis Therapeutics has a drug pipeline for ABR with two molecules in phase 3 for multidrug resistant acinetobacter infections and uncomplicated gonorrhea. MicuRx Pharmaceuticals, Inc. has a molecule called zoliflodacin for methicillin-resistant Staphylococcus aureus infections, in phase 3 clinical trial for launch in China. All these factors bode well for the expansion of the antibiotic resistance market size over the coming years.

Competitive Landscape

The antibiotic resistance market is moderately consolidated with more than 10 key players participating in this space. The global market is dominated by prominent manufacturers - Pfizer, Inc., GlaxoSmith Kline, Johnsons & Johnson, Merck & Co., Inc., Teva Pharmaceutical Industries ltd., Baxter Healthcare Corporation, and others. Majority of these manufacturers are focused on offering of a wide range of antibiotic resistance drugs for multiple indications such as Acute Bacterial Skin and Skin Structure Infections (ABSSSIs), Uncomplicated gonorrhoea, Blood Stream Infections, Community Acquired Pneumonia, Hospital Acquired Pneumonia, etc.

With this, market players are also engaged in expanding their global and regional presence through acquisitions and creating awareness.

  • For instance, in 2019, Fresenius Kabi group launched a patient awareness program and online awareness portal for hospital acquired infections.
  • In August 2016, Teva completed its acquisition of Allergan’s generics business (Actavis Generics) in a US$ 40.5 Bn deal.
  • In Nov 2019, Sandoz announced its agreement to acquire Aspen’s Japanese operations and associated assets, strengthening its position in the world’s third-largest generics market.

Some of the leading companies operating in the market are:

  • Pfizer Inc
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Johnsons & Johnson
  • Baxter Healthcare Corporation
  • Zydus Cadila
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Dr. Reddy’s Laboratories Ltd
  • Mayne Pharma Group Limited
  • Sun Pharmaceutical Industries Ltd
  • Cipla Inc
  • Shanghai Pharmaceutical Group Co., Ltd.
  • Abbott Laboratories

*The list is not exhaustive, and only for representational purposes. Full competitive intelligence available in the report.

Scope of Report



Forecast Period


Historical Data Available for


Market Analysis

USD Million for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Key Countries Covered

  • US
  • Canada
  • Brazil
  • Mexico
  • Argentina
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Poland
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Indonesia
  • Malaysia
  • Australia
  • New Zealand
  • South Africa
  • Turkey
  • North Africa
  • GCC Countries

Key Segments Covered

  • Drug Class
  • Pathogen
  • Disease
  • Mechanism of Action
  • Distribution Channel
  • Region

Key Companies Profiled

  • Pfizer Inc
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Johnsons & Johnson
  • Baxter Healthcare Corporation
  • Zydus Cadila
  • Teva Pharmaceutical Industries Ltd

Report Coverage

  • Market Forecasts
  • Company Share Analysis
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Antibiotic Resistance Market by Category

Drug Class

  • β-Lactam Antibiotics
  • Cephalosporin
  • Quinolones Antibiotics
  • Macrolide Antibiotics
  • Tetracycline
  • Oxazolidinones
  • Others


  • Staphylococcus aureus
  • Streptococcus pneumonia
  • Neisseria gonorrhoeae
  • Enterococcus faecium
  • Escherichia coli
  • Klebsiella pneumonia
  • Shigella
  • Clostridium difficile
  • Others


  • Community Acquired Bacterial Pneumonia (CABP)
  • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  • Complicated Urinary Tract Infection (cUTI)
  • Complicated Intra-Abdominal Infections (cIAI)
  • Blood Stream Infections (BSI)
  • Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • Drug resistant Gonorrheae

Mechanism of Action

  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies


  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA

Key Questions Answered in Report

  • Which is the most lucrative market for antibiotic resistance?

    The U.S. currently captures the maximum market share and leads the global market for antibiotic resistance. The U.S. is expected to witness surging demand for antibiotics for the rest of the forecast period.

  • Which pathogen type holds significant share in the market?

    Staphylococcus aureus holds the highest market share of over 15%. S aureus is a notorious ‘super bug’ and is responsible for causing many infections such as Blood Stream Infections (BSI), Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and Complicated Urinary Tract Infection (cUTI). These infections pose a severe threat to human health.

  • Which drug class is a prominent antibiotic among others?

    Beta Lactam antibiotics are vastly used for the treatment of ABR. Most of the drugs available in market fall under this category. These are used to treat infections such as Community Acquired Bacterial Pneumonia (CABP), Blood Stream Infections (BSI), and Complicated Urinary Tract Infection (cUTI)

  • Which are the leading companies offering antibiotic resistance drugs?

    Some of the prominent companies offering antibiotic resistance drugs are Pfizer Inc, GlaxoSmithKline plc, Merck & Co., Inc., Johnsons & Johnson, Baxter Healthcare Corporation, Zydus Cadila, and Teva Pharmaceutical Industries Ltd.

  • How does spending on R&D in developing regions affect the antibiotic resistance market?

    In Asia Pacific, R&D spending is expected to boost development. China and Japan rank 2rd and 3rd, respectively in R&D spending. R&D spending in Korea is around 4.3% of its GDP, while Japan is 3.6%. These percentages are higher than other developed countries such as the U.S. and Germany, as per UNESCO.

Enquiry before Buying

  • Is this research conducted by Persistence Market Research?

    Yes, the research has been conducted by expert analysts of Persistence Market Research, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.

  • What research methodology is followed by Persistence Market Research?

    Persistence Market Research follows a methodology that encompasses demand-side assessment of the market, and triangulates the same through supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions. Request a detailed methodology.

  • Who are the respondents for primary research?

    Persistence Market Research speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.

  • What are the sources of secondary research?

    Persistence Market Research conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.

  • Is a sample of this report available for evaluation?

    Yes, you can request a sample, and it will be sent to you through an email.

  • How can I buy this report?

    Persistence Market Research provides a secure online payment system to buy reports seamlessly. You can buy the report securely and safely.

Media Release


Opioids Market

The global opioids market is expected to expand at a moderate CAGR of over 3% over the next ten years, and be valued at more than US$ 57 Bn by 2031-end.

Injectable Drug Delivery Market

Global Drug Delivery Devices market had reached to be USD 22 Bn in 2021 and is expected to attain US$ 29 Bn by 2026, growing at a CAGR of 6% during the forecast period of 2021-26.

Generic Oncology Drugs Market

Sales revenue from generic oncology drugs in 2020 was US$ 23 Bn, which is expected to surge to US$ 41.5 Bn by the end of 2031. .

Mitotane Market

The growth of the mitotane market can be attributed to the increased incidence of patient population, which is anticipated to grow significantly in the forecast period..

Our Clients

Our Clients